Psychedelic Research in
Equatorial Guinea
Equatorial Guinea appears to have no publicly documented clinical research ecosystem for psychedelic-assisted therapies, and Blossom's linked trial and stakeholder counts are zero. Open-source evidence points instead to a tightly controlled narcotics environment, with no routine public pathway for psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine or ayahuasca-based treatment.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Equatorial Guinea.
- 1
No public psychedelic clinical-trial footprint is visible in the sources reviewed, consistent with Blossom's zero linked trials and zero active trials.
- 2
Open sources do not reveal an established research institution or treatment centre in Equatorial Guinea that is publicly associated with psychedelic medicine.
- 3
The clearest lawful medicine signal is ketamine as an essential anaesthetic medicine, which is not the same as a regulated psychedelic-psychiatry access route.
- 4
Because open legal texts specific to Equatorial Guinea were not readily identifiable, any compound-by-compound legal mapping should be treated cautiously and updated only from primary legal sources.
- 5
Overall, the country looks best described as a strict/no-access environment for psychedelic therapies rather than a developing clinical programme market.
Research Snapshot
Blossom currently keeps Equatorial Guinea as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Equatorial Guinea has no public, regulated medical framework for psychedelic-assisted therapies and enforces strict national drug control laws; most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are treated as controlled/illegal with no routine medical or reimbursed access outside of authorised research. Ketamine is recognized as an essential anaesthetic agent by WHO and is used in clinical settings as an anaesthetic in low-resource health systems, but there is no publicly documented, reimbursed national...
Regulatory Status
Publicly available sources do not show a regulated national pathway for psychedelic-assisted therapy in Equatorial Guinea, and open-source evidence is too thin to verify any compound-specific scheduling text with confidence. Based on the country's strict drug-control context and the absence of visible trials or services, classical psychedelics should be assumed illegal or non-accessible outside any tightly authorised medical or research use; ketamine may exist in ordinary anaesthetic practice, but there is no public evidence of a psychedelic-mental-health access programme or esketamine pathway.
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Strictly IllegalMedical Access and Reimbursement
Equatorial Guinea has no public, regulated medical framework for psychedelic-assisted therapies and enforces strict national drug control laws; most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are treated as controlled/illegal with no routine...
Open access guide →